<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Management of <z:mp ids='MP_0005048'>thrombosis</z:mp> of the dural sinus and cerebral veins (CVT) includes treatment of the underlying condition, antithrombotic treatment, symptomatic treatment, and the prevention or treatment of complications </plain></SENT>
<SENT sid="1" pm="."><plain>Intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> or subcutaneous low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> should be used in <z:hpo ids='HP_0011009'>acute</z:hpo> CVT to prevent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> propagation and <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> and to increase the chances of recanalization </plain></SENT>
<SENT sid="2" pm="."><plain>Anticoagulation is safe and can be used in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> CVT who have intracranial hemorrhagic lesions </plain></SENT>
<SENT sid="3" pm="."><plain>Endovascular thrombolysis (with or without mechanical <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> disruption) is an experimental treatment to be used in experienced centers for severe cases or patients who fail to improve on anticoagulation </plain></SENT>
<SENT sid="4" pm="."><plain>Local thrombolysis is not useful in patients with large <z:mpath ids='MPATH_124'>infarcts</z:mpath> and impending <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with severe <z:hpo ids='HP_0002315'>headache</z:hpo> and <z:hpo ids='HP_0001085'>papilledema</z:hpo>, intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> can be reduced and symptoms relieved through a therapeutic lumbar puncture </plain></SENT>
<SENT sid="6" pm="."><plain>Hemicraniectomy may be lifesaving in patients with parenchymal lesions leading to <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001250'>seizures</z:hpo> and supratentorial lesions, <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs should be prescribed </plain></SENT>
<SENT sid="8" pm="."><plain>Prophylactic use of these drugs can also be considered for patients with one of these risk factors but should be avoided in patients with neither of them </plain></SENT>
<SENT sid="9" pm="."><plain>To reduce the risk of recurrent <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> of the limbs, <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> are given for a variable period depending on the patient's inherent risk of <z:mp ids='MP_0005048'>thrombosis</z:mp>, aiming at an International Normalized Ratio of 2 to 3.5 </plain></SENT>
<SENT sid="10" pm="."><plain>If CVT is related to a transient risk factor (eg, pregnancy, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>), we recommend <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> for 3 months </plain></SENT>
<SENT sid="11" pm="."><plain>In patients with idiopathic CVT or CVT associated with "mild" <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, the period of anticoagulation must be extended to 6 to 12 months </plain></SENT>
<SENT sid="12" pm="."><plain>In patients with "severe" <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (eg, two or more prothrombotic abnormalities or <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>), <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> should be given for life </plain></SENT>
<SENT sid="13" pm="."><plain>Patients with persistent symptoms of increased intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000572'>visual loss</z:hpo>, or both can be treated with repeated lumbar punctures or a lumboperitoneal shunt </plain></SENT>
<SENT sid="14" pm="."><plain>For the prevention of remote <z:hpo ids='HP_0001250'>seizures</z:hpo>, <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs are recommended for patients with <z:hpo ids='HP_0001250'>seizures</z:hpo> in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase and for those who experience a <z:hpo ids='HP_0001250'>seizure</z:hpo> after the <z:hpo ids='HP_0011009'>acute</z:hpo> phase </plain></SENT>
<SENT sid="15" pm="."><plain>These drugs can also be considered for patients without <z:hpo ids='HP_0001250'>seizures</z:hpo> who have supratentorial hemorrhagic lesions or motor deficits </plain></SENT>
</text></document>